Iron Acquisition Pathways as Targets for Antitubercular Drugs

Area of Science:

• Microbiology
• Drug Discovery
• Infectious Diseases

Background:

• Tuberculosis (TB) is a leading infectious cause of death globally, exacerbated by multi-drug resistant strains.
• Efficient iron acquisition by Mycobacterium tuberculosis is vital for its pathogenesis, impacting DNA biosynthesis and respiration.
• Existing antitubercular drug development faces challenges due to emerging bacterial resistance.

Purpose of the Study:

• To evaluate the potential of targeting iron acquisition systems as a novel strategy for antitubercular drug development.
• To review current research on inhibitors targeting key enzymes and pathways involved in Mycobacterium tuberculosis iron uptake.
• To identify gaps in knowledge and suggest future research directions for combating drug-resistant TB.

Main Methods:

• Review of existing literature on inhibitors targeting mycobactin biosynthesis (MbtI, MbtA) and other relevant pathways.
• Analysis of in vitro and in vivo studies on compounds targeting iron acquisition mechanisms.
• Examination of gene deletion studies to assess the importance of specific iron acquisition pathways.

Main Results:

• Inhibitors of MbtA demonstrated activity in infected mice, while MbtI inhibitors were primarily studied in vitro.
• MmpL3 inhibitors showed antitubercular activity but with potential off-target mechanisms.
• Compounds targeting 4'-phosphopantetheinyl transferase were identified but lacked in vivo validation.

Conclusions:

• Targeting iron acquisition systems presents a promising avenue for developing new antitubercular drugs.
• The redundancy of iron acquisition pathways in Mycobacterium tuberculosis necessitates further investigation into their relative importance.
• In vivo studies using potent and specific inhibitors are crucial for validating targets and advancing drug discovery.